PharmaMar Announces New Advances in Their Compounds Yondelis, plitidepsin and lurbinectedin at ASCO 2016

PharmaMar (MSE:PHM) will present the data obtained from various clinical studies carried out with three of their antitumoral compounds of marine origin: Yondelis®, plitidepsin and lurbinectedin, during the 52nd Congress of the American Society of Clinical Oncology (ASCO), that will be held from June 3rd to 7th in Chicago (USA). At this prestigious international encounter, more than 30.000 oncologists from around the world will meet to discuss, analyze, and exchange knowledge on the progress in the treatment of different types of cancers.

Studies relative to these three molecules, discovered and developed by PharmaMar, will be presented during this congress. These studies have been selected either for oral or poster presentations or poster debates. At ASCO 2016, PharmaMar will present the results of a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with multiple myeloma.

"The principle objective of PharmaMar is to investigate new compounds of a marine origin with a novel mechanism of action that provides a progress in the treatment of certain types of oncological tumors, and an important contribution in healthcare for the patient", explains Dr Nadia Badri, VP Medical Affairs at PharmaMar's oncology business unit.

Dr Arturo Soto, Director of Clinical Development at PharmaMar's Oncology Unit, points out that "the results that we are going to present at ASCO 2016 are an example of how we are progressing in this field, and that we can build on an innovative and promising pipeline of compounds for different types of cancers".

Meeting abstracts are available at http://abstracts.asco.org